We invite you to attend our Official Joint Session with ESC:

• Title: The Therapeutic Conundrum in HFpEF

• When: Friday 30th August, 11:00 – 12:00 CEST

• Where: Room BAKU (Hall 4 – IFEMA MADRID)

• Session Type: Official Joint Session

• Track: Chronic Heart Failure

This session will be chaired by our President-Elect Prof. Doreen Tan (National University of Singapore), who will be joined by our long standing Board Members, Prof. Gheorghe Andrei Dan (Romania) and Prof. Koji Hasegawa (Japan).

Join leading international experts to explore mechanisms and treatment options for heart failure with HFpEF, a major challenge in modern cardiology. Discover new insights into SGLT2 inhibitors, mineralocorticoid receptor antagonists, anti-inflammatory therapy, and GLP-1/GIP pharmacology.

More on the session:

To consider the pathogenetic mechanisms of HFpEF in order to focus on ways to prevent the development of HFpEF and to halt the heart failure pandemic. With rapid ageing and the continuing increase in obesity, heart failure with preserved left ventricular ejection fraction (HFpEF) has become prevalent worldwide. Many patients with HFpEF have complications such as chronic kidney disease and atrial fibrillation: these conditions are thought to form a vicious cycle. Mineralocorticoid receptor antagonists and SGLT2 inhibitors are evidence-based strategies via the primary pathway of renal protection in patients with HFpEF, although multiple other mechanisms are also thought to be involved in these beneficial effects.

Programme:

• 11:00 – Mechanistic insights of SGLT2 inhibitors effectiveness
  Speaker: Gheorghe Andrei Dan, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania

• 11:15 – Mineralocorticoid receptor antagonist drugs in HFpEF
  Speaker: Shelley Zieroth, University of Manitoba, Winnipeg, Canada

• 11:30 – Pharmacotherapy targeting inflammation in HFpEF
  Speaker: Koji Hasegawa, National Hospital Organization Kyoto Medical Center, Kyoto, Japan

• 11:45 – GLP-1 receptor agonist (GLP1-RA) and gastric inhibitory polypeptides (GIPs) in HFpEF
  Speaker: Theresa McDonagh, King’s College Hospital, London, United Kingdom

Don’t miss the opportunity to deepen your understanding of HFpEF therapy with global thought leaders!